Hence, identifying HR-deficiencies by genomic analysis-for instance, <i>BRCA1/2</i> used in triple-negative breast cancer-should be a part of the selection process for PARP inhibitor therapy. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.